ResMed grew revenue 8% and returned over $1 billion to shareholders in 2026
ResMed reported that for fiscal year 2026 revenue grew 8% in constant currency, free cash flow exceeded $1.6 billion, and the company returned more than $1 billion to shareholders. It completed the acquisition of Noctrix Health for $340 million, and proceeds from the MatrixCare sale are being used for an accelerated share repurchase (ASR).
What happened
ResMed said revenue in constant currency jumped 8%, earnings per share (EPS) rose 17%, and free cash flow topped $1.6 billion. The company also returned over $1 billion to shareholders via dividends and share repurchases, 70% more than the prior year.
The $340 million acquisition of Noctrix Health was completed, and on September 1, 2026 the MatrixCare business was sold, with the proceeds earmarked for an accelerated share repurchase (ASR).
Key financial metrics 2026
Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.
What to watch
Watch the constant‑currency revenue growth rate in the 2027 fiscal report.
Check whether 2027 free cash flow remains above $1.6 billion.
Assess 2027 shareholder returns to gauge continuation of dividends and repurchases.
Integration of Noctrix Health and its sales contribution will be detailed in a future report.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Resmed
A notification in your browser or on your phone when we publish about Resmed. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
